<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32528402</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">1664-2392</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>11</Volume>
            <PubDate>
              <Year>2020</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in endocrinology</Title>
          <ISOAbbreviation>Front Endocrinol (Lausanne)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>New Therapies for Advanced Thyroid Cancer.</ArticleTitle>
        <Pagination>
          <StartPage>82</StartPage>
          <MedlinePgn>82</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">82</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fendo.2020.00082</ELocationID>
        <Abstract>
          <AbstractText>Thyroid cancer is the most common endocrine cancer. The discovery of new biomarkers for thyroid cancer has significantly improved the understanding of the molecular pathogenesis of thyroid cancer, thus allowing more personalized treatments for patients with thyroid cancer. Most of the recently discovered targeted therapies inhibit the known oncogenic mechanisms in thyroid cancer initiation and progression such as MAPK pathway, PI3K/Akt-mTOR pathways, or VEGF. Despite the significant advances in molecular testing and the discoveries of new and promising therapeutics, effective treatments for advanced and metastatic, iodine-refractory thyroid cancer are still lacking. Here, we aim to summarize the current understanding of the genetic alterations and the dysregulated pathways in thyroid cancer and to discuss the most recent targeted therapies and immunotherapy for advanced thyroid cancer with a promising anti-tumor activity and clinical benefit.</AbstractText>
          <CopyrightInformation>Copyright © 2020 Laha, Nilubol and Boufraqech.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Laha</LastName>
            <ForeName>Diprajan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nilubol</LastName>
            <ForeName>Naris</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boufraqech</LastName>
            <ForeName>Myriem</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>ZIA BC011286</GrantID>
            <Acronym>ImNIH</Acronym>
            <Agency>Intramural NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016456">Historical Article</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>05</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Front Endocrinol (Lausanne)</MedlineTA>
        <NlmUniqueID>101555782</NlmUniqueID>
        <ISSNLinking>1664-2392</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D049674" MajorTopicYN="N">History, 21st Century</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D035703" MajorTopicYN="Y">Therapies, Investigational</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
          <QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013964" MajorTopicYN="N">Thyroid Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">RAI-refractory</Keyword>
        <Keyword MajorTopicYN="Y">advanced thyroid cancer</Keyword>
        <Keyword MajorTopicYN="Y">immunotherapy</Keyword>
        <Keyword MajorTopicYN="Y">targeted therapies</Keyword>
        <Keyword MajorTopicYN="Y">thyroid cancer</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32528402</ArticleId>
        <ArticleId IdType="pmc">PMC7257776</ArticleId>
        <ArticleId IdType="doi">10.3389/fendo.2020.00082</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. . 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. (2016) 26:1–133. 10.1089/thy.2015.0020</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2015.0020</ArticleId>
            <ArticleId IdType="pmc">PMC4739132</ArticleId>
            <ArticleId IdType="pubmed">26462967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghossein RA, Leboeuf R, Patel KN, Rivera M, Katabi N, Carlson DL, et al. . Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications. Thyroid. (2007) 17:655–61. 10.1089/thy.2007.0061</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2007.0061</ArticleId>
            <ArticleId IdType="pubmed">17696836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silver CE, Owen RP, Rodrigo JP, Rinaldo A, Devaney KO, Ferlito A. Aggressive variants of papillary thyroid carcinoma. Head Neck. (2011) 33:1052–9. 10.1002/hed.21494</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hed.21494</ArticleId>
            <ArticleId IdType="pubmed">20824810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poller DN, Nikiforov YE. Non-invasive follicular thyroid neoplasm with papillary-like nuclei: reducing overtreatment by reclassifying an indolent variant of papillary thyroid cancer. J Clin Pathol. (2016) 69. 10.1136/jclinpath-2016-203930</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jclinpath-2016-203930</ArticleId>
            <ArticleId IdType="pubmed">27387983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nikiforov YE, Erickson LA, Nikiforova MN, Caudill CM, Lloyd RV. Solid variant of papillary thyroid carcinoma: incidence, clinical-pathologic characteristics, molecular analysis, and biologic behavior. Am J Surg Pathol. (2001) 25:1478–84. 10.1097/00000478-200112000-00002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00000478-200112000-00002</ArticleId>
            <ArticleId IdType="pubmed">11717536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McHenry CR, Phitayakorn R. Follicular adenoma and carcinoma of the thyroid gland. Oncologist. (2011) 16:585–93. 10.1634/theoncologist.2010-0405</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.2010-0405</ArticleId>
            <ArticleId IdType="pmc">PMC3228182</ArticleId>
            <ArticleId IdType="pubmed">21482585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howell GM, Hodak SP, Yip L. RAS mutations in thyroid cancer. Oncologist. (2013) 18:926–32. 10.1634/theoncologist.2013-0072</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.2013-0072</ArticleId>
            <ArticleId IdType="pmc">PMC3755930</ArticleId>
            <ArticleId IdType="pubmed">23873720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, Tallini G, et al. . RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. (2003) 88:2318–26. 10.1210/jc.2002-021907</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2002-021907</ArticleId>
            <ArticleId IdType="pubmed">12727991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu G, Mambo Z, Guo S, Hu X, Huang SM, Gollin, et al. . Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab. (2005) 90:4688–93. 10.1210/jc.2004-2281</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2004-2281</ArticleId>
            <ArticleId IdType="pubmed">15928251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, et al. . Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab. (2008) 93:3106–16. 10.1210/jc.2008-0273</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2008-0273</ArticleId>
            <ArticleId IdType="pubmed">18492751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hou P, Ji M, Xing M. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer. (2008) 113:2440–7. 10.1002/cncr.23869</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.23869</ArticleId>
            <ArticleId IdType="pubmed">18831514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Volante M, Landolfi S, Chiusa L, Palestini N, Motta M, Codegone A, et al. . Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. Cancer. (2004) 100:950–7. 10.1002/cncr.20087</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.20087</ArticleId>
            <ArticleId IdType="pubmed">14983490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiltzik D, Carlson DL, Tuttle RM, Chuai S, Ishill N, Shaha A, et al. . Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer. (2006) 106:1286–95. 10.1002/cncr.21739</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.21739</ArticleId>
            <ArticleId IdType="pubmed">16470605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung CK, Little MP, Lubin JH, Brenner AV, Wells SA, Sigurdson AJ, et al. . The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab. (2014) 99:E276–85. 10.1210/jc.2013-2503</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2013-2503</ArticleId>
            <ArticleId IdType="pmc">PMC3913801</ArticleId>
            <ArticleId IdType="pubmed">24248188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, et al. . Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. (2016) 126:1052–66. 10.1172/JCI85271</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI85271</ArticleId>
            <ArticleId IdType="pmc">PMC4767360</ArticleId>
            <ArticleId IdType="pubmed">26878173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest. (1993) 91:1753–60. 10.1172/JCI116385</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI116385</ArticleId>
            <ArticleId IdType="pmc">PMC288155</ArticleId>
            <ArticleId IdType="pubmed">8473515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL, Tallini G. Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol. (2001) 158:987–96. 10.1016/S0002-9440(10)64045-X</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0002-9440(10)64045-X</ArticleId>
            <ArticleId IdType="pmc">PMC1850336</ArticleId>
            <ArticleId IdType="pubmed">11238046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol. (2010) 22:486–97. 10.1016/j.clon.2010.03.013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clon.2010.03.013</ArticleId>
            <ArticleId IdType="pmc">PMC3905320</ArticleId>
            <ArticleId IdType="pubmed">20418080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wendler J, Kroiss M, Gast K, Kreissl MC, Allelein S, Lichtenauer U, et al. . Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany. Eur J Endocrinol. (2016) 175:521–9. 10.1530/EJE-16-0574</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-16-0574</ArticleId>
            <ArticleId IdType="pubmed">27926471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA. (2017) 317:1338–48. 10.1001/jama.2017.2719</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2017.2719</ArticleId>
            <ArticleId IdType="pubmed">28362912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nel CJ, van Heerden JA, Goellner JR, Gharib H, McConahey WM, Taylor WF, et al. . Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases. Mayo Clin Proc. (1985) 60:51–8. 10.1016/S0025-6196(12)65285-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0025-6196(12)65285-9</ArticleId>
            <ArticleId IdType="pubmed">3965822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonhomme B, Godbert Y, Perot G, Al Ghuzlan A, Bardet S, Belleannée G, et al. . Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases. Thyroid. (2017) 27:682–92. 10.1089/thy.2016.0254</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2016.0254</ArticleId>
            <ArticleId IdType="pubmed">28351340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidbauer B, Menhart K, Hellwig D, Grosse J. Differentiated thyroid cancer-treatment: state of the art. Int J Mol Sci. (2017) 18:E1292. 10.3390/ijms18061292</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms18061292</ArticleId>
            <ArticleId IdType="pmc">PMC5486113</ArticleId>
            <ArticleId IdType="pubmed">28629126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDougall IR, Weigel RJ. Recombinant human thyrotropin in the management of thyroid cancer. Curr Opin Oncol. (2001) 13:39–43. 10.1097/00001622-200101000-00008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00001622-200101000-00008</ArticleId>
            <ArticleId IdType="pubmed">11148684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brabant G. Thyroid gland malfunction. MMW Fortschr Med. (2004) 146:30–2, 34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15352703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, et al. . Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid. (1998) 8:737–44. 10.1089/thy.1998.8.737</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.1998.8.737</ArticleId>
            <ArticleId IdType="pubmed">9777742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid. (2010) 20:135–46. 10.1089/thy.2009.0311</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2009.0311</ArticleId>
            <ArticleId IdType="pubmed">20151821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haugen BR. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed?
Cancer. (2017) 123:372–81. 10.1002/cncr.30360</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.30360</ArticleId>
            <ArticleId IdType="pubmed">27741354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta. (2003) 1653:25–40. 10.1016/S0304-419X(03)00016-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0304-419X(03)00016-7</ArticleId>
            <ArticleId IdType="pubmed">12781369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, et al. . Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab. (2010) 95:450–5. 10.1210/jc.2009-0373</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2009-0373</ArticleId>
            <ArticleId IdType="pubmed">19880792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ball DW, Jin N, Rosen DM, Dackiw A, Sidransky D, Xing M, et al. . Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD(6244) J Clin Endocrinol Metab. (2007) 92:4712–8. 10.1210/jc.2007-1184</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2007-1184</ArticleId>
            <ArticleId IdType="pubmed">17878251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, et al. . BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab. (2008) 93:2194–201. 10.1210/jc.2007-2825</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2007-2825</ArticleId>
            <ArticleId IdType="pmc">PMC2435640</ArticleId>
            <ArticleId IdType="pubmed">18381570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vitale G, Dicitore A, Pepe D, Gentilini D, Grassi ES, Borghi MO, et al. . Synergistic activity of everolimus and 5-aza-2'-deoxycytidine in medullary thyroid carcinoma cell lines. Mol Oncol. (2017) 11:1007–22. 10.1002/1878-0261.12070</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1878-0261.12070</ArticleId>
            <ArticleId IdType="pmc">PMC5537710</ArticleId>
            <ArticleId IdType="pubmed">28453190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanly EK, Bednarczyk RB, Tuli NY, Moscatello AL, Halicka HD, Li J, et al. . mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib. Oncotarget. (2015) 6:39702–13. 10.18632/oncotarget.4052</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.4052</ArticleId>
            <ArticleId IdType="pmc">PMC4741856</ArticleId>
            <ArticleId IdType="pubmed">26284586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sadowski SM, Boufraqech M, Zhang L, Mehta A, Kapur P, Zhang Y, et al. . Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis. Oncotarget. (2015) 6:18038–49. 10.18632/oncotarget.3833</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.3833</ArticleId>
            <ArticleId IdType="pmc">PMC4627234</ArticleId>
            <ArticleId IdType="pubmed">25945839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto Y, Matsui J, Matsushima T, Obaishi H, Miyazaki K, Nakamura K, et al. . Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. (2014) 6:18. 10.1186/2045-824X-6-18</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/2045-824X-6-18</ArticleId>
            <ArticleId IdType="pmc">PMC4156793</ArticleId>
            <ArticleId IdType="pubmed">25197551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brauner E, Gunda V, Vanden Borre P, Zurakowski D, Kim YS, Dennett KV, et al. . Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. Oncotarget. (2016) 7:17194–211. 10.18632/oncotarget.7839</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.7839</ArticleId>
            <ArticleId IdType="pmc">PMC4941380</ArticleId>
            <ArticleId IdType="pubmed">26943572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gunda V, Gigliotti B, Ashry T, Ndishabandi D, McCarthy M, Zhou Z, et al. . Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer. Int J Cancer. (2019) 144:2266–78. 10.1002/ijc.32041</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.32041</ArticleId>
            <ArticleId IdType="pubmed">30515783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cantara S, Bertelli E, Occhini R, Regoli M, Brilli L, Pacini F, et al. . Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer. Endocrine. (2019) 64:122–9. 10.1007/s12020-019-01865-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-019-01865-5</ArticleId>
            <ArticleId IdType="pubmed">30762153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hutton JE, Wang X, Zimmerman LJ, Slebos RJ, Trenary IA, Young JD, et al. . Oncogenic KRAS and BRAF drive metabolic reprogramming in colorectal cancer. Mol Cell Proteomics. (2016) 15:2924–38. 10.1074/mcp.M116.058925</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/mcp.M116.058925</ArticleId>
            <ArticleId IdType="pmc">PMC5013308</ArticleId>
            <ArticleId IdType="pubmed">27340238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. (2013) 13:184–99. 10.1038/nrc3431</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3431</ArticleId>
            <ArticleId IdType="pmc">PMC3791171</ArticleId>
            <ArticleId IdType="pubmed">23429735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. (2003) 63:1454–7. 10.3410/f.717987086.793472329</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3410/f.717987086.793472329</ArticleId>
            <ArticleId IdType="pubmed">12670889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, et al. . BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PT. Oncogene C. (2003) 22:4578–80. 10.1038/sj.onc.1206706</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1206706</ArticleId>
            <ArticleId IdType="pubmed">12881714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrari SM, Fallahi P, Politti U, Materazzi G, Baldini E, Ulisse S, et al. . Molecular targeted therapies of aggressive thyroid cancer. Front Endocrinol. (2015) 6:176. 10.3389/fendo.2015.00176</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fendo.2015.00176</ArticleId>
            <ArticleId IdType="pmc">PMC4653714</ArticleId>
            <ArticleId IdType="pubmed">26635725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fallahi P, Ruffilli I, Elia G, Ragusa F, Ulisse S, Baldini E, et al. . Novel treatment options for anaplastic thyroid cancer. Expert Rev Endocrinol Metab. (2017) 12:279–288. 10.1080/17446651.2017.1340155</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/17446651.2017.1340155</ArticleId>
            <ArticleId IdType="pubmed">30058884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. . Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. (2010) 467:596–9. 10.1038/nature09454</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature09454</ArticleId>
            <ArticleId IdType="pmc">PMC2948082</ArticleId>
            <ArticleId IdType="pubmed">20823850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, et al. . Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid. (2013) 23:1277–83. 10.1089/thy.2013.0057</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2013.0057</ArticleId>
            <ArticleId IdType="pmc">PMC3967415</ArticleId>
            <ArticleId IdType="pubmed">23489023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, et al. . Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. (2016) 17:1272–82. 10.1016/S1470-2045(16)30166-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(16)30166-8</ArticleId>
            <ArticleId IdType="pmc">PMC5532535</ArticleId>
            <ArticleId IdType="pubmed">27460442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rothenberg SM, McFadden DG, Palmer EL, Daniels GH, Wirth LJ.
Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res. (2015) 21:1028–35. 10.1158/1078-0432.CCR-14-2915</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-14-2915</ArticleId>
            <ArticleId IdType="pubmed">25549723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. 
Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. (2018) 36:7–13. 10.1200/JCO.2017.73.6785</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.73.6785</ArticleId>
            <ArticleId IdType="pmc">PMC5791845</ArticleId>
            <ArticleId IdType="pubmed">29072975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurzrock R, Ball DW, Zahurak ML, Nelkin BD, Subbiah V, Ahmed S, et al. . A Phase I Trial of the VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced solid tumors and differentiated thyroid cancers. Clin Cancer Res. (2019) 25. 10.1158/1078-0432.CCR-18-1881</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-18-1881</ArticleId>
            <ArticleId IdType="pmc">PMC7038784</ArticleId>
            <ArticleId IdType="pubmed">31186313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA, et al. . Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res. (2012) 18:2056–65. 10.1158/1078-0432.CCR-11-0563</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-11-0563</ArticleId>
            <ArticleId IdType="pmc">PMC5157199</ArticleId>
            <ArticleId IdType="pubmed">22241789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, et al. . Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. (2013) 368:623–32. 10.1056/NEJMoa1209288</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1209288</ArticleId>
            <ArticleId IdType="pmc">PMC3615415</ArticleId>
            <ArticleId IdType="pubmed">23406027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, et al. . Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study. Clin Cancer Res. (2018) 24:1546–53. 10.1158/1078-0432.CCR-17-2297</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-17-2297</ArticleId>
            <ArticleId IdType="pubmed">29301825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schneider TC, de Wit D, Links TP, van Erp NP, van der Hoeven JJ, Gelderblom H.
Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial. J Clin Endocrinol Metab. (2017) 102:698–707. 10.1210/jc.2017-00661</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2017-00661</ArticleId>
            <ArticleId IdType="pubmed">27870581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. 
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. (2014) 384:319–28. 10.1016/S0140-6736(14)60421-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(14)60421-9</ArticleId>
            <ArticleId IdType="pmc">PMC4366116</ArticleId>
            <ArticleId IdType="pubmed">24768112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, et al. . A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer. (2015) 121:2749–56. 10.1002/cncr.29395</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.29395</ArticleId>
            <ArticleId IdType="pmc">PMC4803478</ArticleId>
            <ArticleId IdType="pubmed">25913680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. . Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. (2015) 372:621–30. 10.1056/NEJMoa1406470</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1406470</ArticleId>
            <ArticleId IdType="pubmed">25671254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vieira JM, Santos SC, Espadinha C, Correia I, Vag T, Casalou C, et al. . Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. Eur J Endocrinol. (2005) 153:701–9. 10.1530/eje.1.02009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/eje.1.02009</ArticleId>
            <ArticleId IdType="pubmed">16260429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karaca Z, Tanriverdi F, Unluhizarci K, Ozturk F, Gokahmetoglu S, Elbuken G, et al. . VEGFR1 expression is related to lymph node metastasis and serum VEGF may be a marker of progression in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol. (2011) 164:277–84. 10.1530/EJE-10-0967</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-10-0967</ArticleId>
            <ArticleId IdType="pubmed">21097568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown SR, Hall A, Buckley HL, Flanagan L, Gonzalez de Castro D, Farnell K, et al. . Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial. BMC Cancer. (2019) 19:582. 10.1186/s12885-019-5541-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-019-5541-4</ArticleId>
            <ArticleId IdType="pmc">PMC6567392</ArticleId>
            <ArticleId IdType="pubmed">31200667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, et al. . E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. (2008) 122:664–71. 10.1002/ijc.23131</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.23131</ArticleId>
            <ArticleId IdType="pubmed">17943726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okamoto K, Kodama K, Takase K, Sugi NH, Yamamoto Y, Iwata M, et al. . Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. (2013) 340:97–103. 10.1016/j.canlet.2013.07.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2013.07.007</ArticleId>
            <ArticleId IdType="pubmed">23856031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Na KJ, Choi H. Immune landscape of papillary thyroid cancer and immunotherapeutic implications. Endocr Relat Cancer. (2018) 25:523–31. 10.1530/ERC-17-0532</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/ERC-17-0532</ArticleId>
            <ArticleId IdType="pubmed">29507047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, et al. . Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. (2005) 11:2947–53. 10.1158/1078-0432.CCR-04-1469</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-04-1469</ArticleId>
            <ArticleId IdType="pubmed">15837746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin YM, Sung WW, Hsieh MJ, Tsai SC, Lai HW, Yang SM, et al. . High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma. PLoS ONE. (2015) 10:e0142656. 10.1371/journal.pone.0142656</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0142656</ArticleId>
            <ArticleId IdType="pmc">PMC4642967</ArticleId>
            <ArticleId IdType="pubmed">26562534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Massari F, Santoni M, Ciccarese C, Santini D, Alfieri S, Martignoni G, et al. . PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. Cancer Treat Rev. (2015) 41:114–21. 10.1016/j.ctrv.2014.12.013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctrv.2014.12.013</ArticleId>
            <ArticleId IdType="pubmed">25586601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mehnert JM, Varga A, Brose MS, Aggarwal RR, Lin CC, Prawira A, et al. 
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. BMC Cancer. (2019) 19:196
10.1186/s12885-019-5380-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-019-5380-3</ArticleId>
            <ArticleId IdType="pmc">PMC6399859</ArticleId>
            <ArticleId IdType="pubmed">30832606</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
